NCT05292443 2024-02-23Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated Primary Liver CancerGeneplus-Beijing Co. Ltd.Withdrawn
NCT03220009 2018-10-03Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal MelanomaNational Cancer Institute (NCI)Phase 2 Withdrawn